Home › Pagkabigo ng Puso › Missouri › Kansas City
Pag-aaral pangklinika para sa Pagkabigo ng Puso sa Kansas City, MO
Isang pag-aaral para sa Pagkabigo ng Puso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Kansas City. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Nagre-recruitPhase 3
- Research Site, Kansas City
- Research Site, Kansas City
ELEVATE-HFpEF Clinical Study
Nagre-recruit
- Saint Lukes Mid America Heart Institute, Kansas City
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Nagre-recruitPhase 3
- Kansas City VA Medical Center, Kansas City
- North Kansas City Hospital, North Kansas City · 2 mi ang layo
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Nagre-recruitPhase 3
- Kansas City VA Medical Center, Kansas City
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
Nagre-recruitPhase 3
- Research Site, Kansas City
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
Nagre-recruit
- Saint Luke's Hospital of Kansas City, Kansas City
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
Nagre-recruitPhase 3
- Saint Luke's Hospital of Kansas City, Kansas City
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Nagre-recruitPhase 3
- Research Site, Kansas City
- Research Site, Kansas City
The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
Nagre-recruitObservasyonal na pag-aaral
- St. Luke's Hospital of Kansas City, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Nagre-recruitPhase 3
- CON-10002 Kansas City, MO Investigative Site, Kansas City
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Nagre-recruitPhase 3
- Kansas City, MO Investigative Site 10002, Kansas City
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
Nagre-recruitPhase 2
- Local Institution - 145, Kansas City
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Nagre-recruitObservasyonal na pag-aaral
- Kansas City, Kansas City
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
Nagre-recruitPhase 3
- Tenax Investigational Site, Kansas City
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)
Nagre-recruitObservasyonal na pag-aaral
- St. Luke's Mid-America Heart Institute, Kansas City
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
Nagre-recruitPhase 3
- Clinical Research Consultants, JCCT Co, Kansas City
Assessment of CCM in HF With Higher Ejection Fraction
Nagre-recruit
- St. Lukes Hospital Kansas City (Mid America Heart Institute), Kansas City
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Nagre-recruitPhase 3
- FIN-10002 Kansas City, MO Investigational Site, Kansas City
A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction
Nagre-recruitPhase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
Nagre-recruit
- St. Lukes/ Mid-American Heart Institute, Kansas City
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
Nagre-recruitPhase 3
- Children's Mercy Hospital Kansas City - Cardiology, Kansas City
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
Nagre-recruit
- St. Luke's Hospital, Kansas City
CCM OPEN HF Registry
Nagre-recruitObservasyonal na pag-aaral
- Saint Luke's Hospital Mid America Heart Institute, Kansas City
- Saint Luke's Hospital of Kansas City, Kansas City
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
Nagre-recruitObservasyonal na pag-aaral
- Saint Luke's Health System, Kansas City
Pag-aaral para sa Pagkabigo ng Puso sa ibang lungsod
- New York City, NY51 pag-aaral
- Boston, MA44 pag-aaral
- Dallas, TX42 pag-aaral
- Houston, TX37 pag-aaral
- Cleveland, OH33 pag-aaral
- Chicago, IL31 pag-aaral
- Philadelphia, PA31 pag-aaral
- San Francisco, CA29 pag-aaral
- St. Louis, MO26 pag-aaral
- Durham, NC26 pag-aaral
- Atlanta, GA25 pag-aaral
- Baltimore, MD24 pag-aaral
Iba pang pag-aaral sa Kansas City
- Kanser sa Suso34 pag-aaral
- Non-Small Cell Lung Cancer31 pag-aaral
- Kanser (lahat ng uri)22 pag-aaral
- Kanser sa Baga19 pag-aaral
- Colorectal Cancer16 pag-aaral
- Metastatic Cancer15 pag-aaral
- Acute Myeloid Leukemia15 pag-aaral
- Kanser sa Prostate14 pag-aaral
- Kanser sa Ovary12 pag-aaral
- Type 2 Diabetes11 pag-aaral
- Obesity11 pag-aaral
- Sakit sa Puso at Ugat ng Dugo11 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 7, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.